TTK and esophageal cancer: To date, one phase I clinical trial has been conducted to study the effect of multi-peptide vaccination (TTK, URLC10, KOC1, VEGFR1, VEGFR2) in combination with chemoradiation therapy in esophageal cancer (NCT00632333), demonstrating peptide-specific cytotoxic T cell immune responses and durable complete responses in 54.5% of patients.208